Evidence map›Paper›PMID 42571438›Full record

ArticleKidney international reports2026

Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.

Juliette Leon, Elise Ducrocq, Marie-Camille Lafargue, Dominique Bertrand, Lucie Maigret, Mohamad Zaidan, Arthur Michon Colin, Eric Thervet, Antoine Durrbach, Nassim Kamar and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Juliette LeonDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Elise DucrocqDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Marie-Camille LafargueDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Dominique BertrandDepartment of Nephrology, Transplantation and Hemodialysis, Rouen University Hospital, Rouen, France.
Lucie MaigretDepartment of Nephrology, Hypertension, Dialysis and Kidney Transplantation, Tours University Hospital, Tours, France.
Mohamad ZaidanDepartment of Nephrology, Dialysis, Transplantation, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Arthur Michon ColinDepartment of Nephrology, Dialysis, Transplantation, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Eric ThervetDepartment of Nephrology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Antoine DurrbachDepartment of Nephrology and Transplantation, AP-HP Henri-Mondor Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM) U1186, Gustave Roussy Institute, Université Paris-Saclay, Créteil, France.
Nassim KamarDepartment of Nephrology and Organ Transplantation, Axe TImE, Toulouse Rangueil University Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1291, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), University Paul Sabatier, Toulouse, France.
Betoul SchvartzDepartment of Nephrology, Dialysis and Transplantation, Reims University Hospital, Reims, France.
Nicolas BouvierDepartment of Nephrology, Dialysis and Transplantation, Caen Normandie University Hospital, Caen, France.
Manal MazloumDepartment of Nephrology, Dialysis and Transplantation, Lapeyronie University Hospital, Montpellier, France.
Hamza Naciri BennaniDepartment of Nephrology, Hemodialysis, Apheresis and Kidney Transplantation, Félix-Guyon University Hospital, Saint-Denis, La Réunion, France.
Manon GuezennecDepartment of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Edouard Herriot University Hospital, Lyon, France.
Dalila Es-SalehDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Antoine TrogerDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Carole BurgerDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Marie-Bénédicte Le StangDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Camille RogerDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Frank HullekesDepartment of Surgery, Center for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Olivier AubertDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Julien ZuberDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Leonardo V RiellaDepartment of Surgery, Center for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Vincent AudardNephrology and Renal Transplantation Department, Assistance Publique-Hôpitaux de Paris, French Rare Disease Center "Idiopathic Nephrotic Syndrome", Henri Mondor University Hospital, Créteil, France.
Dany AnglicheauDepartment of Kidney Diseases and Metabolism, Transplantation and Clinical Immunology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, and Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Recurrent focal segmental glomerulosclerosis (FSGS, rFSGS) is a severe complication after kidney transplantation, often resistant to standard therapies and requiring prolonged apheresis. Combined depletion of plasma cells (anti-CD38) and B cells (anti-CD20) has emerged as a potential strategy; however, multicenter real-world data integrating clinical, biological, and histological characterization remain limited. Methods: We retrospectively studied 17 kidney transplant recipients with rFSGS treated with daratumumab (anti-CD38) administered after and/or in combination with anti-CD20 therapy across 12 French centers. Patients were clinically and histologically characterized at treatment initiation. Clinical response, safety, and longitudinal antinephrin antibody trajectories were assessed. Results: Median time from recurrence to daratumumab initiation was 5 months. All patients had previously received B-cell-depleting therapy. After the first daratumumab course (1-8 injections), 7 patients (41%) achieved complete remission (CR) and 4 (24%) achieved partial remission (PR), allowing discontinuation of apheresis in all responders. Median response time was 24 days. During a median follow-up of 8 months, 3 responders relapsed but regained remission after retreatment. Median proteinuria decreased from 3.9 g/g to 1.4 g/g at 1 month ( Conclusion: In this multicenter real-world cohort, combined plasma cell and B-cell depletion was associated with meaningful remission rates in refractory rFSGS and was accompanied by dynamic changes in antinephrin antibodies in selected cases. Prospective trials are warranted to define optimal patient selection and dosing, and to clarify its place in therapy.

Indexed as

anti-CD38 antibodyantinephrin antibodyfocal segmental glomerulosclerosiskidney transplantationrecurrence glomerular disease

Identifiers

PMID42571438
PMCPMC13452287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.